Get the Stockscreener App
55.83
3.00%
1.625
After Hours:
55.20
-0.63
-1.13%
Spruce Biosciences Inc stock is traded at $55.83, with a volume of 14,857.
It is up +3.00% in the last 24 hours and down -33.13% over the past month.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The pipeline products of the company include Tralesinidase Alfa (TA-ERT), and Tildacerfont/ Cortibon, a Companion Diagnostic, developed in partnership with HMNC Brain Health.
See More
Previous Close:
$54.20
Open:
$54.12
24h Volume:
14,857
Relative Volume:
0.27
Market Cap:
$59.76M
Revenue:
$7.10M
Net Income/Loss:
$-39.43M
P/E Ratio:
-59.39
EPS:
-0.94
Net Cash Flow:
$-46.50M
1W Performance:
-4.11%
1M Performance:
-33.13%
6M Performance:
-89.73%
1Y Performance:
-90.34%
1-Day Range:
$53.00
$55.83
1-Week Range:
$51.78
$62.94
52-Week Range:
$7.26
$543.38
Spruce Biosciences Inc Stock (SPRB) Company Profile
Name
Spruce Biosciences Inc
Sector
Industry
Phone
(415) 655-4168
Address
611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
Compare SPRB vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRB
Spruce Biosciences Inc
|
55.83 | 58.02M | 7.10M | -39.43M | -46.50M | -0.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.27 | 123.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
766.66 | 83.60B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
748.72 | 46.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.65 | 43.11B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
297.04 | 34.79B | 4.98B | 69.60M | 525.67M | 0.5198 |
Spruce Biosciences Inc Stock (SPRB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-25 | Initiated | Oppenheimer | Outperform |
| Dec-03-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-28-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Dec-11-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-11-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-14-24 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-14-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-14-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-14-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-14-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-21-24 | Initiated | Guggenheim | Buy |
| Dec-17-21 | Initiated | Oppenheimer | Outperform |
| Dec-10-21 | Initiated | The Benchmark Company | Speculative Buy |
| Nov-16-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-19-21 | Initiated | H.C. Wainwright | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Credit Suisse | Outperform |
| Nov-03-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-20 | Initiated | SVB Leerink | Outperform |
View All
Spruce Biosciences Inc Stock (SPRB) Latest News
SPRB Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Spruce Biosciences (SPRB) Gains FDA Support for Accelerated Approval Pathway - Finviz
SPRB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Spruce Biosciences to Present at Upcoming Investor Conferences in March - Investing News Network
Spruce Biosciences, Inc. (NASDAQ:SPRB) Given Average Rating of "Hold" by Analysts - MarketBeat
Spruce Biosciences Touts MPS IIIB Data, Targets Q4 BLA Submission at Oppenheimer Conference - MarketBeat
Spruce Biosciences Inc. (SPRB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Total debt per share of Spruce Biosciences, Inc. – NASDAQ:SPRB - TradingView
Carlyle Group Inc. Expands Stake in Spruce Biosciences Inc. - GuruFocus
Millennium group (SPR B) joint Schedule 13G shows ~103K shares (~9.6%) - Stock Titan
HC Wainwright Has Positive Outlook for SPRB FY2025 Earnings - MarketBeat
SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy - Stocktwits
Regulatory De-Risking and Extended Runway Underpin Maintained Buy Rating on Spruce Biosciences - TipRanks
SPRB Analyst Rating Update: HC Wainwright Lowers Price Target | - GuruFocus
Carlyle Group Inc. Takes Position in Spruce Biosciences, Inc. $SPRB - MarketBeat
Spruce Biosciences Stock Falls 5% Despite Positive Outcomes From Two Recent Type B Meetings With FDA - Nasdaq
Spruce Biosciences Gains After Positive FDA Type B Meetings On TA-ERT - Nasdaq
Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB) - Business Wire
Spruce Biosciences, Inc. shares recorded a significant increase, rising by 8.16% in a single day. - Bitget
Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Investing News Network
Biotech working on neurological drugs joins Oppenheimer stage - Stock Titan
Spruce Biosciences recently announced that its candidate drug TA-ERT for Sanfilippo syndrome type B (also known as MPS IIIB) received positive feedback during a Type B meeting with the U.S. Food and Drug Administration (FDA). - Bitget
SPRB PE Ratio & Valuation, Is SPRB Overvalued - Intellectia AI
SPRB Should I Buy - Intellectia AI
Spruce Biosciences: TA-ERT’s Promising Long-Term Data and Priority Review Voucher Upside Underpin Reiterated Buy and $220 Target - TipRanks
Experimental enzyme therapy stabilizes skills for 6 years in fatal disorder - Stock Titan
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team - BioSpace
Spruce Biosciences Makes Two SVP Appointments - Contract Pharma
Spruce Biosciences (NASDAQ:SPRB) Shares Up 0.6%Time to Buy? - MarketBeat
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™ - BioSpace
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium - Investing News Network
Harbour BioMed Exercises Warrant to Acquire 3.8% of Spruce Biosciences Inc. - intellectia.ai
Big-Pharma Partner Harbour BioMed Boosts Stake In Spruce Biosciences - Benzinga
Harbour BioMed Acquires Stake in U.S. Partner Spruce Biosciences, Signaling Strategic Shift in Chinese Biotech - IndexBox
Harbour BioMed Acquires 3.8% of Spruce Biosciences, Enhancing Strategic Partnership - Intellectia AI
Harbour BioMed Expands Stake in Spruce Biosciences (SPRB) - GuruFocus
Harbour BioMed Exercises Agreement to Buy Spruce Biosciences Common Stock - Contract Pharma
Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences - Intellectia AI
Harbour BioMed Acquires 3.8% Stake in Spruce Biosciences (SPRB) - Intellectia AI
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deep - GuruFocus
Harbour BioMed Exercises Warrant To Acquire Stake In Spruce Biosciences - Nasdaq
HBM Holdings Deepens Ties With Spruce Biosciences via Warrant Exercise - TipRanks
Harbour BioMed buys into Spruce to back new hormone disorder drug - Stock Titan
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration - Barchart.com
Harbour BioMed takes stake in Spruce Biosciences - MSN
Spruce Biosciences (SPRB) Price Target Increased by 10.02% to 235.11 - Nasdaq
Spruce Biosciences, Inc. (NASDAQ:SPRB) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Spruce Biosciences Secures Up to $50 Million in Growth Capital from Avenue Capital - BioSpace
Spruce Biosciences secures up to $50 million in growth capital from Avenue Capital - marketscreener.com
Spruce Biosciences Signs Multiple Financing Agreements - TradingView — Track All Markets
Spruce Biosciences Inc Stock (SPRB) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.71%
0.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):